Clinical trials: Chronic Obstruct Airways Disease
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD (Chronic Obstructive Pulmonary Disease)
The Safety and Effectiveness of Taneasy and Actein in COPD Patients
To evaluate the safety and efficacy of Taneasy 600mg granules and Actein effervescent tablets 600MG administered twice daily for 14 days in treatment of COPD Disease.
- Trial name
- NCT06688292
- Testing
- Taneasy 600mg granules, Actein effervescent 600mg
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Bun Yao Biotechnology Co., Ltd
Pulmonary Disease, Chronic Obstructive
A Cross-sectional Study on COPD Prevalence
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality worldwide and hence, estimating its prevalence is important.
- Trial name
- NCT03028207
- Testing
- Medical tests, Questionnaire
- Where
- 20 sites in Spain
- Volunteers
- 9,362 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Obstructive Pulmonary Disease
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development…
- Trial name
- GLIMMER (NCT03084796)
- Testing
- CHF 5259, Tiotropium Bromide 18 µg Inhalation Capsule
- Where
- 112 sites in United States
- Volunteers
- 733 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).
The purpose of this study is to evaluate the level of satisfaction experienced by asthma or chronic obstructive pulmonary disease (COPD) patients when using the Fluticasone/Salmeterol HFA Metered Dose Inhaler (MDI) with counter…
- Trial name
- NCT00404261
- Testing
- Fluticasone/Salmeterol HFA
- Where
- 4 sites in Australia
- Volunteers
- 132 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-centered, randomized, placebo-controlled, double-blind, parallel group, trial evaluating 2 doses of mepolizumab against placebo given every 4 weeks through subcutaneous (SC) injection.
- Trial name
- NCT02105961
- Testing
- Mepolizumab
- Where
- 169 sites in United States, Argentina and 13 more
- Volunteers
- 674 people
- Sponsor
- GlaxoSmithKline
Asthma, COPD
The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients
A Multi-centre, retrospective study describing the impact of PCCM standardized implementation on healthcare management among Asthma or COPD or Asthma-COPD overlap patients in Tianjin city of China, using real world electronic…
- Conditions
- Asthma, COPD, Asthma-COPD Overlap
- Trial name
- PCCM-IMPACTS (NCT04905420)
- Where
- China
- Volunteers
- 288,538 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
The Effects of RPL554 on Top of Standard COPD Reliever Medications
This study evaluates the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in a randomised sequence: 1. salbutamol, 2.
- Trial name
- NCT02542254
- Testing
- Salbutamol, Ipratropium, RPL554
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Asthma, COPD
A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI)
This study will compare the patient handling of Flutiform® pMDI (pressurised metered dose inhaler) and a breath activated device (BAI).
- Trial name
- NCT01739387
- Testing
- Flutiform® pMDI and Breath Actuated Inhaler (BAI)
- Where
- 2 sites in United Kingdom
- Volunteers
- 332 people
- Sponsor
- Mundipharma Research Limited
Pulmonary Disease, Chronic Obstructive
12 / 48 wk Pivotal PFT vs PBO in COPD II
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782509
- Testing
- Olodaterol (BI 1744)
- Where
- 51 sites in United States, China and 2 more
- Volunteers
- 644 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects
GW642444 is a potent and selective long-acting beta2 agonist; GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist (or anticholinergic) bronchodilator.
- Trial name
- DB2113208 (NCT00976144)
- Testing
- GSK573719
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
Subjects who have not used the ELLIPTA™ inhaler nor the DISKUS™ inhaler in the past 6 months will be screened to participate in the study.
- Trial name
- NCT01868009
- Testing
- ELLIPTA, DISKUS
- Where
- 17 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a randomised, double-blind, parallel-group, multi-centre study evaluating 15 milligram (mg) twice daily/ Bi-daily (BID) of losmapimod versus placebo, in addition to standard of care (SoC).
- Trial name
- NCT02299375
- Testing
- Losmapimod tablets, Salbutamol MDI
- Where
- 36 sites in Argentina, Brazil and 6 more
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
COPD
Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study was to observe the Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01636401
- Testing
- aclidinium bromide 400 μg
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler.
- Trial name
- NCT00281567
- Testing
- Tiotropium, Respimat SMI, HandiHaler
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
Asthma, Chronic Obstructive Pulmonary Disease
Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease
This clinical trial will include healthy volunteers, COPD patients and asthmatic patients who will breathe He/O2 78:22, He/O2 65:35 and medical air consecutively in a randomised order.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Healthy
- Trial name
- NCT00801307
- Testing
- spirometer
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Air Liquide SA
Chronic Obstructive Pulmonary Disease
Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive Disease
The primary objective of this non-interventional study is to evaluate daily symptom variability in COPD patients. The secondary objectives are; to evaluate effects of COPD symptoms on the morning activities of patients, to…
- Trial name
- NCT01110564
- Where
- 19 sites in Turkey (Türkiye)
- Volunteers
- 515 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Study of Patient With Frequent COPD Exacerbations
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent…
- Trial name
- PRIORITY-COPD (NCT07221981)
- Where
- 30 sites in Russia
- Volunteers
- 2,024 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)
Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung disease characterized by chronic bronchitis and/or emphysema, resulting in breathlessness, cough and sputum.
- Trial name
- DACOTA (NCT01285167)
- Testing
- Daxas
- Where
- 605 sites in Germany
- Volunteers
- 3,645 people
- Sponsor
- AstraZeneca
COPD
A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of RO5024118 following repeated inhalation in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01009424
- Testing
- R7103
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.